o-(chloroacetylcarbamoyl)fumagillol and Meningioma

Meningiomas are relatively common (22%) vascular brain tumors. 3-11% of meningiomas are malignant, and defy currently available therapy. Inhibition of neovascularization is one potential strategy for treating these hypervascular tumors. Inhibition of tumor-induced angiogenesis by TNP-470 (previously termed AGM-1470), a synthetic analogue of fumagillin, was tested on the growth of human non-malignant and malignant meningiomas in nude mice. TNP-470 significantly inhibited tumor neovascularization and tumor growth of both non-malignant and malignant meningiomas. TNP-470 is now in human trial and should be tested for efficacy in treating malignant or recurrent aggressive meningiomas.

Topics: Animals; Antibiotics, Antineoplastic; Body Weight; Cell Transplantation; Cyclohexanes; Female; Humans; Meningeal Neoplasms; Meningioma; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Neovascularization, Pathologic; Neurofibromatoses; O-(Chloroacetylcarbamoyl)fumagillol; Regional Blood Flow; Sesquiterpenes; Transplantation, Heterologous